陈荣伴.不同剂量沙利度胺联合化疗方案治疗老年多发性骨髓瘤的临床疗效对比研究[J].内科急危重症杂志,2016,22(6):
扫码阅读全文
|
| DOI： |
| 中文关键词: 多发性骨髓瘤 沙利度胺 VAD方案 老年患者 |
| 英文关键词:Multiple myeloma Thalidomide VADSregimens Old patients |
| 基金项目: |
|
| 摘要点击次数: 2348 |
| 全文下载次数: 3399 |
| 中文摘要: |
| 目的 探讨不同剂量沙利度胺联合化疗方案治疗老年多发性骨髓瘤的临床疗效。方法 选取老年多发性骨髓瘤患者共61例随机分为对照组(n=31)和观察组(n=30)。对照组给予沙利度胺(400mg/d) VAD化疗方案,观察组给予沙利度胺(100mg/d) VAD化疗方案。比较两组临床疗效、临床指标及不良反应。结果 观察组和对照组治疗有效率分别为76.7%和83.9%,两组比较无统计学差异(P＞0.05)。治疗后,两组患者血M蛋白、尿素氮、骨髓浆细胞计数均显著降低,血红蛋白及Kamofsky评分均显著提高,与治疗前比较具有统计学差异(P＜0.05)；两组患者治疗后血M蛋白、血红蛋白、尿素氮、骨髓浆细胞计数及Kamofaky评分比较无统计学差异(P＞0.05)。 观察组便秘、口鼻粘膜干燥、乏力、头晕等不良反应发生率显著低于对照组,组间比较具有统计学差异(P＜0.05)；两组腹胀、恶心、皮疹等发生率比较无统计学差异(P＞0.05)。结论 100mg/d沙利度胺或400mg/d沙利度胺联合VAD方案治疗老年多发性骨髓瘤的临床疗效近似,而100mg/d沙利度胺联合VAD方案治疗多发性骨髓瘤的不良反应更轻。 |
| 英文摘要: |
| Objective To evaluate the effect of different dose of thalidomide combined with chemotherapySregimens on old patients with multiple myeloma. Methods 61 old patients with multiple myeloma were randomly divided into control group (n=31)and observation group(n=30). The control group was given to thalidomide(400mg/d)combined with VAD chemotherapySregimens. The observation group was given to thalidomide(100mg/d)combined with VAD chemotherapySregimens. The clinical efficacy, clinical indicators and adverse reactions were compared between the two groups. Results The clinical efficacy of observation group and control group respectively was 76.7% and 83.9%, had no significant differences between the two groups (P＞0.05). After treatment, the serum M protein, ureaSnitrogen and marrow plasmocyte amount of two group significantly decreased, the hemoglobin and Kamofsky score significantly increased, compared with before treatment differences statistically significant (P<0.05). The serum M protein, ureaSnitrogen, marrow plasmocyte amount, hemoglobin and Kamofsky score of two groups had no significant differences (P＞0.05). The rate of constipation, oro-nasal mucosa dry, weak and swirl in observation group significantly lower than control group, showed significant differences between the two groups (P<0.05). The rate of abdominalSdistension, nausea and rash of two groups had no significant differences(P＞0.05). Conclusion 100mg/d thalidomide or 400mg/d thalidomide combined with VAD chemotherapySregimens treat with multiple myeloma have similar clinical efficacy, but 100mg/d thalidomide combined with VAD chemotherapySregimens with lightSside-effect. |
|
|
|
|
